Bradley & Co Private Wealth Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Bradley & Co Private Wealth Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.7K	Hold	370	–	–	﹤0.01%	177
2026 Q1	$3.52K	Hold	370	–	–	﹤0.01%	170
2025 Q4	$2.89K	Buy	+370	New	+$2.67K	﹤0.01%	176
2023 Q4	–	Sell	-370	Closed	-$2.62K	–	199
2023 Q3	$2.62K	Hold	370	–	–	﹤0.01%	150
2023 Q2	$2.6K	Hold	370	–	–	﹤0.01%	153
2023 Q1	$3.09K	Hold	370	–	–	﹤0.01%	147
2022 Q4	$4.25K	Hold	370	–	–	0.01%	141
2022 Q3	$5K	Hold	370	–	–	0.01%	141
2022 Q2	$4K	Hold	370	–	–	﹤0.01%	152
2022 Q1	$6K	Hold	370	–	–	0.01%	133
2021 Q4	$5K	Hold	370	–	–	﹤0.01%	138
2021 Q3	$5K	Hold	370	–	–	﹤0.01%	144
2021 Q2	$6K	Hold	370	–	–	0.01%	149
2021 Q1	$4K	Buy	+370	New	+$3.81K	﹤0.01%	152

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jupiter Topco New York $245B AUM

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Bradley & Co Private Wealth Management's BCRX Position: Q2 2026 in Review

Bradley & Co Private Wealth Management held its BioCryst Pharmaceuticals (BCRX) position steady in Q2 2026 at 370 shares worth $3.7K. The position accounts for ﹤0.01% of the portfolio, ranked #177.

Bradley & Co Private Wealth Management first reported a position in BCRX in Q1 2021 and has held it in 14 quarters since. The position peaked at $6K in Q1 2022. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

Bradley & Co Private Wealth Management held 370 shares of BioCryst Pharmaceuticals worth $3.7K as of Q2 2026.
Bradley & Co Private Wealth Management left its BioCryst Pharmaceuticals share count unchanged in Q2 2026.
BioCryst Pharmaceuticals made up ﹤0.01% of Bradley & Co Private Wealth Management's portfolio in Q2 2026, its #177 holding.
Bradley & Co Private Wealth Management first reported a position in BioCryst Pharmaceuticals in Q1 2021 and has held it in 14 quarters since.
Bradley & Co Private Wealth Management's BioCryst Pharmaceuticals position peaked at $6K in Q1 2022.
318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Bradley & Co Private Wealth Management's 13F filing for Q2 2026, filed 10 Aug 2026.